BARICIPAC

Serial Number 79369234
Registration 7416516
700

Registration Progress

Application Filed
Sep 21, 2022
Under Examination
Approved for Publication
Apr 2, 2024
Published for Opposition
Apr 2, 2024
Registered
Jun 18, 2024

Trademark Image

BARICIPAC

Basic Information

Serial Number
79369234
Registration Number
7416516
Filing Date
September 21, 2022
Registration Date
June 18, 2024
Published for Opposition
April 2, 2024
Drawing Code
5

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 18, 2024
Registration
Registered
Classes
005

Rights Holder

Pacific Pharmaceuticals Pte Ltd.

13
Address
101 CECIL STREET,
#17-07 TONG ENG BUILDING SINGAPORE 06953
SG

Ownership History

Pacific Pharmaceuticals Pte Ltd.

Original Applicant
13
SG

Pacific Pharmaceuticals Pte Ltd.

Owner at Publication
13
SG

Pacific Pharmaceuticals Pte Ltd.

Original Registrant
13
SG

Legal Representation

Attorney
Sang N. Dang

USPTO Deadlines

Next Deadline
1686 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-06-18)
Due Date
June 18, 2030
Grace Period Ends
December 18, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

28 events
Date Code Type Description Documents
Dec 4, 2024 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Dec 3, 2024 FIMP P FINAL DISPOSITION PROCESSED Loading...
Sep 18, 2024 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Jun 18, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jun 18, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 16, 2024 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Apr 2, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 2, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 27, 2024 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Mar 27, 2024 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Mar 13, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 29, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 27, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Feb 27, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Feb 27, 2024 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Feb 27, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Feb 8, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 7, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 7, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 5, 2023 RFNT P REFUSAL PROCESSED BY IB Loading...
Aug 14, 2023 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Aug 14, 2023 RFRR P REFUSAL PROCESSED BY MPU Loading...
Jul 8, 2023 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Jul 7, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 3, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
May 16, 2023 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
May 12, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 11, 2023 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Mineral dietary supplements for humans; Pharmaceutical drugs comprising Janus Kinase (JAK) inhibitors for the treatment of severe Coronavirus infection, alopecia areata and severe rheumatoid arthritis

Classification

International Classes
005